MedTrace Logo

Study of HS235 for Assessing the Pharmacokinetics, Safety, and Pharmacodynamics in Overweight/Obese Healthy Subjects

NCT06714825 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 39

Last updated 2025-12-30

No results posted yet for this study

Summary

Study of HS235 for Assessing the Pharmacokinetics, Safety, and Pharmacodynamics of HS235 in Overweight and Obese Otherwise Healthy Subjects

Conditions

  • Overweight and Obesity

Interventions

BIOLOGICAL

HS235

Up to 4 Single and 3 Multiple Ascending Doses

DRUG

Placebo

Subcutaneous Injection

Sponsors & Collaborators

  • 35Pharma Inc

    lead INDUSTRY

Principal Investigators

  • Monique Champagne, M.Sc. · VP, Clinical Operations

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
QUADRUPLE
Model
SEQUENTIAL

Eligibility

Min Age
40 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-11-28
Primary Completion
2025-12-02
Completion
2025-12-02

Countries

  • Canada

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06714825 on ClinicalTrials.gov